Skip to main content

Table 7 Distribution of patients in subgroups by treatment with corresponding pCR rates

From: Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast

  

n (pCR)

  

ddAT – Tamoxifen (n = 98)

ddAT + Tamoxifen (n = 98)

ER+

HER2+

11 (1)

10 (0)

 

HER2-

46 (1)

42 (0)

 

HER2 status missing

1 (0)

0 (0)

 

Total

58 (2)

52 (0)

ER-

HER2+

12 (1)

13 (0)

 

HER2-

28 (6)

33 (8)

 

Total

40 (7)

46 (8)

Total

 

98 (9)

98 (8)

  1. ddAT, dose-dense Adriblastin (Doxorubicin) and Taxotere (Docetaxel); ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; pCR, pathological complete remission.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us